BCEL Atreca Inc

Price (delayed)

$6.66

Market cap

$245.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.69

Enterprise value

$152.11M

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique ...

Highlights
BCEL's debt has shrunk by 100% YoY
Atreca's quick ratio has decreased by 35% YoY but it has increased by 13% from the previous quarter
Atreca's equity has increased by 29% YoY but it has decreased by 10% from the previous quarter
BCEL's net income is down by 29% YoY and by 7% QoQ
Atreca's EPS has decreased by 20% YoY

Key stats

What are the main financial stats of BCEL
Market
Shares outstanding
36.89M
Market cap
$245.72M
Enterprise value
$152.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$98.38M
EBITDA
-$95.41M
Free cash flow
-$92.79M
Per share
EPS
-$2.69
Free cash flow per share
-$2.52
Book value per share
$5.38
Revenue per share
$0
TBVPS
$6.53
Balance sheet
Total assets
$240.84M
Total liabilities
$42.24M
Debt
$0
Equity
$198.6M
Working capital
$178.58M
Liquidity
Debt to equity
0
Current ratio
13.48
Quick ratio
12.74
Net debt/EBITDA
0.98
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37.5%
Return on equity
-42.6%
Return on invested capital
-64.2%
Return on capital employed
-43.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCEL stock price

How has the Atreca stock price performed over time
Intraday
-0.75%
1 week
3.42%
1 month
13.07%
1 year
-48.61%
YTD
-58.76%
QTD
-21.83%

Financial performance

How have Atreca's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.18M
Net income
-$98.39M
Gross margin
N/A
Net margin
N/A
BCEL's net income is down by 29% YoY and by 7% QoQ
The operating income has contracted by 24% YoY and by 7% from the previous quarter

Growth

What is Atreca's growth rate over time

Valuation

What is Atreca stock price valuation
P/E
N/A
P/B
1.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atreca's EPS has decreased by 20% YoY
The stock's price to book (P/B) is 41% less than its last 4 quarters average of 2.1
Atreca's equity has increased by 29% YoY but it has decreased by 10% from the previous quarter

Efficiency

How efficient is Atreca business performance
The company's return on invested capital has surged by 57% YoY and by 6% QoQ
BCEL's return on assets is up by 8% year-on-year
BCEL's ROE is down by 2.2% QoQ

Dividends

What is BCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCEL.

Financial health

How did Atreca financials performed over time
BCEL's total assets is up by 46% YoY but it is down by 8% from the previous quarter
Atreca's quick ratio has decreased by 35% YoY but it has increased by 13% from the previous quarter
BCEL's debt is 100% lower than its equity
BCEL's debt has shrunk by 100% YoY
Atreca's equity has increased by 29% YoY but it has decreased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.